KDR and neoplasm: Based on the fact that SB218078 is designed as a competitive binding inhibitor against chk1, we inferred that SB218078 could inhibit tumor angiogenesis by regulating the transcription of ZEB1 and thereby inhibiting the expression of VEGFR2.